A Multi-country Study on the Prescription Patterns of Short Acting Beta-2 Agonist (SABA) and Its Potential Effects on Asthma Control: A Cross-Sectional Study on SABA Use in Asthma
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 8,617
- 试验地点
- 1
- 主要终点
- The main outcome will be a categorisation of SABA prescription in asthma patients.
研究概览
简要总结
The aim of the study is to describe the prescribing pattern of the different types of medications which are used to treat asthma, across multiple countries.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female patients ≥12 years-old
- •Documented diagnosis with Asthma as per medical records.
- •Have had ≥3 consultations with the HCP at study start date
- •After full explanation, a patient or legal guardian must have signed an informed consent document indicating that they understand the purpose of and the procedures required for the study and are willing to participate in the study.
排除标准
- •Patient with a diagnosis of chronic obstructive pulmonary disease or other chronic respiratory disease different from Asthma.
- •An acute or chronic condition that, in the investigator's opinion, would limit the patient's ability to participate in this study
结局指标
主要结局
The main outcome will be a categorisation of SABA prescription in asthma patients.
时间窗: 12 months retrospective from index date
Mild asthma patients will be categorised into 5 groups according to the number of SABA and ICS prescriptions in the 12 months prior to their index date (initial exposure window): 1. No prescriptions for asthma inhalers 2. Appropriate SABA prescription with no ICS 3. Appropriate SABA prescription with ICS 4. SABA over-prescription with no ICS 5. SABA over-prescription with ICS Moderate/severe asthma patients will be categorised into 2 groups according to the number of SABA and ICS prescriptions in the 12 months prior to their index date: 1. Appropriate SABA prescription on top of maintenance therapy 2. SABA over-prescription on top of maintenance therapy
次要结局
未报告次要终点